This article is more than 5 years old. Information may no longer be current.

MacuLogix launches AdaptDx for early AMD detection

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MacuLogix Inc. has launched AdaptDx in Europe at the Euretina meeting in Vienna.

The dark adaptometer is designed for clinical use to detect age-related macular degeneration at a subclinical stage before structural changes in the retina are visible, according to a company press release.

“Our technology and support can enable earlier diagnosis of age-related macular degeneration, when intervention and treatment are most effective,” MacuLogix president and CEO William McPhee said. “Not only can the routine use of the AdaptDx help prevent blindness caused by AMD, we also believe it has the potential to relieve the societal costs associated with preventable vision loss in an aging population.”